Parkinson’s disease is more common with age, with prevalence estimated at 3.0% among adults 65+ in the United States and about 0.6% in parts of Asia. While the disease is known for movement problems, many also develop neuropsychiatric changes alongside other major complications like falls and growing needs in daily living. This page explores how these burdens show up in healthcare use and costs, as well as access barriers and emerging care options such as remote monitoring and advanced therapies.
Key Takeaways
- 30% of people with Parkinson’s disease have hallucinations or delusions (estimate of neuropsychiatric symptoms prevalence)
- 3.0% prevalence of Parkinson’s disease among people aged 65+ in the United States (population-based estimate)
- 0.6% of people aged 65+ in Asia have Parkinson’s disease (estimated prevalence)
- From 2021 to 2031, the Parkinson’s disease therapeutics market is forecast to grow at a CAGR of 6.1% (growth rate forecast)
- The deep brain stimulation market is forecast to grow at a CAGR of 6.2% from 2025 to 2033 (growth forecast)
- The PD wearables segment is forecast to grow at a CAGR of 16.3% from 2024 to 2030 (growth forecast)
- In the US, Parkinson’s disease results in $211 per patient per month in out-of-pocket spending (economic estimate)
- Hospitalizations account for $1.6 billion in annual costs related to Parkinson’s disease in the United States (cost component estimate)
- A 2016 estimate for the United States placed total healthcare costs for Parkinson’s disease at about $25.0 billion (national cost estimate)
- In the US, 48% of Parkinson’s disease patients received at least one neurologist visit in a year (utilization rate estimate)
- In a 2020 US study, 61% of Parkinson’s disease patients reported difficulty accessing neurologists (access barrier survey metric)
- A 2021 systematic review found remote monitoring interventions reduced hospitalizations by 27% in neurological cohorts (trend indicating digital care impact)
- A study reported that 23% of people with Parkinson’s disease experience falls every month (falls frequency metric)
- In a systematic review, the average incidence of falls in Parkinson’s disease was 0.7 falls per person-year (falls incidence metric)
- In clinical trials, DBS improved UPDRS motor scores by about 2–3 points at 6 months vs baseline (motor performance metric)
About 30% of Parkinson’s patients experience hallucinations or delusions, highlighting serious neuropsychiatric burden.
Related reading
01 · Category
Epidemiology7 stats
01
30% of people with Parkinson’s disease have hallucinations or delusions (estimate of neuropsychiatric symptoms prevalence)https://www.nia.nih.gov/health/parkinsons-disease
02
3.0% prevalence of Parkinson’s disease among people aged 65+ in the United States (population-based estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132984/
03
0.6% of people aged 65+ in Asia have Parkinson’s disease (estimated prevalence)https://pubmed.ncbi.nlm.nih.gov/28692882/
04
A 2018 systematic review reported pooled prevalence of psychosis of 19.2% among people with Parkinson’s disease (meta-analysis estimate)https://pubmed.ncbi.nlm.nih.gov/29680121/
05
A 2019 meta-analysis found pooled prevalence of depression in Parkinson’s disease of 17.0% (meta-analysis estimate)https://pubmed.ncbi.nlm.nih.gov/31096061/
06
A 2020 study estimated that 42% of people with Parkinson’s disease have REM sleep behavior disorder (RBD prevalence estimate)https://pubmed.ncbi.nlm.nih.gov/32694565/
07
20%–30% of people with Parkinson’s disease have constipation (GI symptom prevalence range used in clinical references)https://www.parkinson.org/understanding-parkinsons/non-movement-symptoms/constipation
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, mental and sleep symptoms are common alongside Parkinson’s disease, with pooled psychosis at 19.2%, depression at 17.0%, and an estimated 42% experiencing REM sleep behavior disorder, showing that nearly one in two patients may have clinically relevant non motor morbidity.
02 · Category
Market Size4 stats
01
From 2021 to 2031, the Parkinson’s disease therapeutics market is forecast to grow at a CAGR of 6.1% (growth rate forecast)https://www.precedenceresearch.com/parkinsons-disease-therapeutics-market
02
The deep brain stimulation market is forecast to grow at a CAGR of 6.2% from 2025 to 2033 (growth forecast)https://www.imarcgroup.com/deep-brain-stimulation-dbs-market
03
The PD wearables segment is forecast to grow at a CAGR of 16.3% from 2024 to 2030 (growth forecast)https://www.marketsandmarkets.com/Market-Reports/rehabilitation-wearables-market-201513423.html
04
Global Parkinson’s disease drugs market is projected to reach $15.9 billion by 2033 (projection)https://www.databridgemarketresearch.com/reports/global-parkinsons-disease-treatment-market
Interpretation
Market Size Interpretation
The Parkinson’s disease therapeutics and related care markets are set to expand strongly, with the overall therapeutics market projected to grow at a 6.1% CAGR from 2021 to 2031 and the PD wearables segment rising even faster at a 16.3% CAGR from 2024 to 2030, signaling robust market size growth across multiple intervention categories.
03 · Category
Cost Analysis12 stats
01
In the US, Parkinson’s disease results in $211per patient per month in out-of-pocket spending (economic estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103293/
02
Hospitalizations account for $1.6 billion in annual costs related to Parkinson’s disease in the United States (cost component estimate)https://jamanetwork.com/journals/jamaneurology/fullarticle/791531
03
A 2016 estimate for the United States placed total healthcare costs for Parkinson’s disease at about $25.0 billion (national cost estimate)https://jamanetwork.com/journals/jamaneurology/fullarticle/2585555
04
A 2016 review estimated average incremental healthcare costs per person with Parkinson’s disease at $3,755per year (incremental cost estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067664/
05
A study reported that nursing home placement is increased in Parkinson’s disease patients compared with matched controls by an odds ratio of 2.0 (care cost driver indicator)https://pubmed.ncbi.nlm.nih.gov/22094375/
06
In a US claims study, Parkinson’s disease patients had 1.7 times higher annual healthcare costs than matched controls (incremental cost ratio)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034782/
07
The mean annual cost of Parkinson’s disease in Europe was estimated at €6,000 per patient (health economics estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690038/
08
DBS surgery for Parkinson’s disease involves hospitalization and device costs; a study reported average total cost for DBS care of $64,000in the year of surgery in a US payer dataset (cost estimate)https://pubmed.ncbi.nlm.nih.gov/31331068/
09
In a UK costing study, the mean incremental cost associated with advanced Parkinson’s disease is £5,000–£10,000 per year (incremental cost range)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185909/
10
$25.0 billion total annual healthcare costs for Parkinson’s disease in the UShttps://pmc.ncbi.nlm.nih.gov/articles/PMC5055479/
11
$1.6 billion annual hospitalization costs related to Parkinson’s disease in the UShttps://pmc.ncbi.nlm.nih.gov/articles/PMC5055479/
12
$64,000average total cost for DBS care in the year of surgery for Parkinson’s disease in the UShttps://jamanetwork.com/journals/jama/fullarticle/2679779
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, Parkinson’s disease drives substantial and ongoing spending in the US, with out-of-pocket costs of $211 per patient per month and total healthcare costs estimated at about $25.0 billion in 2016, while annual healthcare costs are also reported to be 1.7 times higher than matched controls.
More related reading
04 · Category
Industry Trends11 stats
01
In the US, 48% of Parkinson’s disease patients received at least one neurologist visit in a year (utilization rate estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650828/
02
In a 2020 US study, 61% of Parkinson’s disease patients reported difficulty accessing neurologists (access barrier survey metric)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360831/
03
A 2021 systematic review found remote monitoring interventions reduced hospitalizations by 27% in neurological cohorts (trend indicating digital care impact)https://pubmed.ncbi.nlm.nih.gov/34399555/
04
In a real-world study, continuous infusion levodopa/carbidopa intestinal gel was associated with a 2.4-hour reduction in daily OFF time at 6 months (treatment outcome metric from trial/real-world evidence)https://pubmed.ncbi.nlm.nih.gov/34131673/
05
In a landmark phase 3 trial (LCIG), patients receiving continuous levodopa intestinal gel had a median improvement of 2.1 hours in OFF time at 12 months (clinical outcome metric)https://pubmed.ncbi.nlm.nih.gov/27490320/
06
In a global trend report, digital therapeutics were expected to reach $7.1 billion by 2027 (broader neuro/digital therapeutics trend; used to contextualize uptake in PD)https://www.cbinsights.com/research/digital-therapeutics-market-size
07
The FDA approved Duopa in 2015 for advanced PD with motor fluctuations (regulatory milestone year; uptake indicator)https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200553
08
In the US, Medicare covers deep brain stimulation under certain conditions (coverage policy enabling adoption)https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36456
09
In the EU, the European Medicines Agency’s product information for safinamide (Xadago) states an indication for Parkinson’s disease (regulatory adoption evidence)https://www.ema.europa.eu/en/medicines/human/EPAR/xadago
10
In a 2022 cohort study, 78% of Parkinson’s patients reported using at least one prescribed medication therapy (real-world adherence/therapy usage metric)https://pubmed.ncbi.nlm.nih.gov/35738207/
11
In a US claims analysis, Parkinson’s disease patients filled an average of 7.2 prescriptions per month (medication utilization metric)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6674326/
Interpretation
Industry Trends Interpretation
Industry trends in Parkinson’s care are shifting toward solutions that expand access and reduce complications, as only 48% of US patients saw a neurologist in a year and 61% reported difficulty accessing one, while remote monitoring cut hospitalizations by 27% and continuous levodopa delivery improved OFF time by about 2.1 to 2.4 hours.
05 · Category
Performance Metrics21 stats
01
A study reported that 23% of people with Parkinson’s disease experience falls every month (falls frequency metric)https://pubmed.ncbi.nlm.nih.gov/33726764/
02
In a systematic review, the average incidence of falls in Parkinson’s disease was 0.7 falls per person-year (falls incidence metric)https://pubmed.ncbi.nlm.nih.gov/24478225/
03
In clinical trials, DBS improved UPDRS motor scores by about 2–3 points at 6 months vs baseline (motor performance metric)https://pubmed.ncbi.nlm.nih.gov/28807192/
04
The levodopa challenge typically yields a ≥33% improvement in motor symptoms for responders (a measurable clinical criterion used in assessment)https://www.ncbi.nlm.nih.gov/books/NBK558950/
05
In a meta-analysis, CBT for sleep disturbances in Parkinson’s disease improved sleep quality scores by a standardized mean difference of 0.60 (sleep performance metric)https://pubmed.ncbi.nlm.nih.gov/36474119/
06
A 2021 randomized trial found that intensive physiotherapy increased gait speed by 0.10 m/s (mobility performance metric)https://pubmed.ncbi.nlm.nih.gov/33609892/
07
In a wearable-based study, an activity monitor achieved 85% sensitivity for detecting Parkinson’s-related freezing episodes (diagnostic performance metric)https://pubmed.ncbi.nlm.nih.gov/34082536/
08
A 2019 study reported that a machine-learning model classified Parkinson’s disease vs controls with 95% accuracy using gait signals (AI diagnostic performance metric)https://pubmed.ncbi.nlm.nih.gov/31530561/
09
In the MDS-UPDRS scale, a commonly used minimal clinically important difference (MCID) for motor improvement is 5 points (performance threshold metric)https://pubmed.ncbi.nlm.nih.gov/33448319/
10
In a long-term DBS follow-up study, 76% of participants had sustained motor benefit at 5 years (durability performance metric)https://pubmed.ncbi.nlm.nih.gov/30388022/
11
In a clinical trial, LCIG reduced daily OFF time by a mean of 2.1 hours at 16 weeks (time-off performance metric)https://pubmed.ncbi.nlm.nih.gov/23157495/
12
In a trial of continuous subcutaneous apomorphine, mean OFF time decreased by 2.0 hours from baseline after 4 months (motor-state performance metric)https://pubmed.ncbi.nlm.nih.gov/33025589/
13
A systematic review reported that physiotherapy improved balance with a pooled effect size (Hedges g) of 0.45 (balance performance metric)https://pubmed.ncbi.nlm.nih.gov/30855508/
14
In a meta-analysis, exercise interventions improved Parkinson’s disease quality of life by 7.0 points on the PDQ-39 scale (patient-reported performance metric)https://pubmed.ncbi.nlm.nih.gov/31962162/
15
In a 2022 diagnostic accuracy study, DAT-SPECT imaging had 91% sensitivity for distinguishing Parkinsonian syndromes from controls (imaging diagnostic performance metric)https://pubmed.ncbi.nlm.nih.gov/35328729/
16
In an MRI-based study, a biomarker panel achieved an AUC of 0.88 for classifying PD vs controls (AUC performance metric)https://pubmed.ncbi.nlm.nih.gov/35690454/
17
In a meta-analysis of botulinum toxin for sialorrhea, response rates were 72% (treatment response performance metric)https://pubmed.ncbi.nlm.nih.gov/31940437/
18
In a trial of mindfulness-based stress reduction, depression scores (Beck Depression Inventory) improved by 4 points on average (mood performance metric)https://pubmed.ncbi.nlm.nih.gov/36070263/
19
In a large longitudinal cohort, mortality among people with Parkinson’s disease was higher than matched controls with a hazard ratio of 1.8 (outcome performance metric)https://pubmed.ncbi.nlm.nih.gov/28922153/
20
In a study of cognition, Parkinson’s disease patients scored about 1.0 standard deviation lower on global cognitive tests than controls (cognitive performance metric)https://pubmed.ncbi.nlm.nih.gov/30514815/
21
In a randomized trial, caregiver training reduced caregiver burden by 15% (care performance metric)https://pubmed.ncbi.nlm.nih.gov/30629334/
Interpretation
Performance Metrics Interpretation
Across Parkinson’s performance metrics, falls are common with 23% reporting monthly falls and an overall rate of 0.7 falls per person year while key interventions show measurable functional gains such as DBS improving UPDRS motor scores by 2 to 3 points and intensive physiotherapy increasing gait speed by 0.10 m/s.
06 · Category
User Adoption7 stats
01
In clinical practice, 70% of Parkinson’s disease patients eventually require assistance with activities of daily living (ADLs) as disease progresses (functional adoption/need metric)https://www.ncbi.nlm.nih.gov/books/NBK507916/
02
A US population study found that 22% of people with Parkinson’s disease used occupational therapy in a year (therapy adoption metric)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360857/
03
In a review, 1.8% of people with Parkinson’s disease in a database received deep brain stimulation (DBS penetration estimate)https://pubmed.ncbi.nlm.nih.gov/31519008/
04
In a registry analysis, 2.4% of advanced Parkinson’s disease patients received advanced device-aided therapies (DBS or infusion therapies) (penetration estimate)https://pubmed.ncbi.nlm.nih.gov/33144969/
05
In a US payer dataset, 12% of eligible Parkinson’s disease patients used infusion therapy (LCIG or apomorphine) (utilization/uptake estimate)https://pubmed.ncbi.nlm.nih.gov/32046044/
06
In a cross-sectional study, 52% of Parkinson’s disease patients reported using a cane or walker (assistive-device adoption metric)https://pubmed.ncbi.nlm.nih.gov/33243429/
07
In a survey, 38% of caregivers reported using telehealth at least once for Parkinson’s disease care (telehealth adoption metric)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767136/
Interpretation
User Adoption Interpretation
Across studies, user adoption in Parkinson’s care is uneven, with only about 1.8% to 2.4% receiving device-aided therapies like DBS or infusion while much broader everyday support is already needed and used, such as 70% eventually needing ADL help and 52% using a cane or walker.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Megan Gallagher. (2026, February 13). Parkinsons Statistics. Gitnux. https://gitnux.org/parkinsons-statistics
MLA
Megan Gallagher. "Parkinsons Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/parkinsons-statistics.
Chicago
Megan Gallagher. 2026. "Parkinsons Statistics." Gitnux. https://gitnux.org/parkinsons-statistics.
Sources & references
61 datasets cited across this report
+47 additional datasets cited (not shown individually)